Indian Pharma industry moving towards formulations

Indian Pharma industry is slowing moving up the value chain. Earlier it used to manufacture active pharmaceutical ingredient at low cost compared to world. Now with competition from China, which provides API at 15-20% low cost, it makes sense to shift focus elsewhere. Many top companies like Lupin, Novartis, Ranbaxy have less revenue stream from API than from formulations. There could also be the reason that formulation business has grown faster than APIs for some companies. API is low scale commodity with low margin. Moreover, with a large number of patent expiries in developed markets like the US and Europe, Indian companies, with skills to develop and manufacture low-cost generic drugs, see a much more lucrative opportunity there than utilising their capacities for manufacturing APIs.
Read More

  • No Image
    Pfizer Ltd

    Pfizer Ltd is an India-based pharmaceutical company. It has a portfolio of approximately 140 products across over 15 therapeutic areas. It is engaged in manufacturing, marketing

  • No Image
    Pharmaids Pharmaceuticals Ltd

    Pharmaids Pharmaceuticals Limited (PPL) has begun its journey in 1989 with an objective to serve the society with better and affordable medicine in Ayurveda and Allopath. It has